Haematological malignancies

Gene: MSH6

Green List (high evidence)

MSH6 (mutS homolog 6, Ensemblv90)
EnsemblGeneIds (GRCh38): ENSG00000116062
EnsemblGeneIds (GRCh37): ENSG00000116062
OMIM: 600678, ClinGen, DECIPHER
MSH6 is in 1 panel

1 review

Bryony Thompson (Royal Melbourne Hospital)

Green List (high evidence)

Haematological malignancies can be a feature of biallelic MMR deficiency
Created: 7 Feb 2026, 6:07 p.m. | Last Modified: 7 Feb 2026, 6:07 p.m.
Panel Version: 0.44

Phenotypes
Mismatch repair cancer syndrome 3, MONDO:0030841

Publications

Details

Mode of Inheritance
BIALLELIC, autosomal or pseudoautosomal
Sources
  • Expert Review Green
  • Curated sources
Phenotypes
  • Class: Familial cancer syndrome
  • Lymphoma, ALL, MDS, AML
  • Constitutional mismatch repair deficiency syndrome (Lynch syndrome)
  • Brain tumors, gastrointestinal cancers, GI (colon), ovarian, uterine, CNS, other
OMIM
600678
ClinGen
MSH6
DECIPHER
MSH6
Clinvar variants
Variants in MSH6
Penetrance
None
Publications
Panels with this gene

History Filter Activity

Note: This information shows the history of the gene symbol, not the gene entity. Where the gene symbol for a gene has changed, this history may reference a different gene to the entry you are currently viewing.
7 Feb 2026, Gel status: 3

Entity classified by Genomics England curator

Bryony Thompson (Royal Melbourne Hospital)

Gene: msh6 has been classified as Green List (High Evidence).

7 Feb 2026, Gel status: 3

Created, Added New Source, Set mode of inheritance, Set publications, Set Phenotypes

Bryony Thompson (Royal Melbourne Hospital)

gene: MSH6 was added gene: MSH6 was added to Haematological malignancies cancer susceptibility. Sources: Curated sources,Expert Review Green Mode of inheritance for gene: MSH6 was set to BIALLELIC, autosomal or pseudoautosomal Publications for gene: MSH6 were set to 27881370; 28297620 Phenotypes for gene: MSH6 were set to Class: Familial cancer syndrome; Lymphoma, ALL, MDS, AML; Constitutional mismatch repair deficiency syndrome (Lynch syndrome); Brain tumors, gastrointestinal cancers, GI (colon), ovarian, uterine, CNS, other